
Sign up to save your podcasts
Or
With the newly announced launch of the phase 3 trial on Paltusotine, Crinetics new nonpeptide oral drug candidate for acromegaly, we asked Dr. Alessandra Casagrande, their new Medical Science Director, to give us her perspectives on this study.
4.9
88 ratings
With the newly announced launch of the phase 3 trial on Paltusotine, Crinetics new nonpeptide oral drug candidate for acromegaly, we asked Dr. Alessandra Casagrande, their new Medical Science Director, to give us her perspectives on this study.
3,331 Listeners
111,059 Listeners
1,228 Listeners
1,110 Listeners
44 Listeners
195 Listeners
7 Listeners
2,679 Listeners
289 Listeners
14 Listeners